Tag: human experimentation

UK’s approval of self-amplifying vaccines is a catastrophic “mistake”

In 2018, Imperial College London entered into a partnership with the Coalition for Epidemic Preparedness Innovations (“CEPI”) to develop a self-amplifying RNA vaccine platform (“saRNA”) to enable tailored vaccine production against multiple viral pathogens.

“The consortium aims to develop ‘RapidVac’, a synthetic saRNA vaccine platform, which will be used to produce vaccines against influenza, rabies and Marburg, with hopes to move these products to Phase I clinical testing in humans,” Pharma Times wrote.

In June 2020, a team at Imperial College London announced that it had developed a vaccine against covid that used “bits of genetic code (called self-amplifying RNA).” 

“Once inside the cell, the self-amplifying RNA produces copies of itself, which can instruct the cell’s own machinery to make the coronavirus protein,” Imperial College said.  “The muscle cells will then produce lots of the spike protein … Some of the proteins will be presented on the surface of the muscle cells … When the immune system comes across these tiny spikes, it recognises them as foreign.”

Imperial College completed Phase I and II clinical trials, but due to the approval and rollout of several other covid injections, the decision was made not to proceed with trials in the UK.  Instead, the team focused their UK efforts on “developing self-amplifying RNA technology to adapt to new variants, to boost other vaccines and to be deployed against future pandemic threats,” Imperial College threatened in a January 2021 article.

Imperial College has also been working on saRNA vaccines for rabies, Chikungunya, Ebola, Lassa and Marburg. It has been a key pioneer in saRNA vaccine research, particularly through its collaborations with VaxEquity and AstraZeneca, but it is the US company Arcturus Therapeutics’ saRNA vaccine that has been approved for use in the UK.

On 2 January 2026, the Medicines and Healthcare products Regulatory Agency (“MHRA”) approved Kostaive (also known as Zapomeran), a self-amplifying mRNA (“sa-mRNA”) covid vaccine developed by Arcturus Therapeutics, for use in adults aged 18 years and older. 

Kostaive uses sa-mRNA technology, which includes genetic instructions for both the SARS-CoV-2 spike protein and a viral replicase enzyme, enabling the mRNA to amplify itself within cells.  The stated aim is to enhance immune response with lower doses.

As Pharma Phorum described it, “Unlike regular mRNA vaccines, sa-mRNA vaccines – as their name suggests – instruct the body to make more mRNA and protein to boost the immune response, rather than relying on a finite dose which results in protection waning over time.”

“It is administered as a single 0.5 ml booster dose by intramuscular injection into the upper arm … Once injected, the sa-mRNA in lipid nanoparticles enters cells, where it directs production of the spike protein. The immune system recognises this protein as foreign,” Pharmacally wrote.

Recognising a protein in our bodies as foreign is the problem.  As Dr. Mike Yeadon explained in a video last month, making our bodies’ cells manufacture a foreign protein that our immune systems would attack results in autoimmune conditions, a self-to-self attack where our immune systems attack our own cells, thinking they are foreign invaders that need to be killed.

It would seem the vaccine industry is not satisfied with the effectiveness of mRNA vaccines waning over time, what they might refer to as “waning protection,” and so are seeking to extend the risk of autoimmune conditions through the use of saRNA “vaccines.”

Keep reading

NHS Greenlights Controversial Puberty Blocker Trials, Will Inject Over 200 Kids as Young as 10

The UK’s National Health Service (NHS) has approved two clinical trials to study the effects of puberty blockers on children, involving up to 226 participants, with some as young as 10 years old.

The trials, set to begin recruitment in early 2025, aim to “gather evidence” on the impacts of these drugs after a ban on their routine NHS prescription earlier this year.

The Daily Mail reports:

They will be injected with the drugs to examine whether they could safely be used in future to help young people change their bodies and become more like the gender they self-identify as, rather than their gender at birth.

Researchers dismissed accusations that the trial could amount to ‘coercing’ children into taking the drugs, which potentially damage fertility, bone density and brain development.

They insisted it would be safe because they have planned the ‘most rigorous and safest study design’ which will involve ‘close monitoring’ of any potential side-effects and risks.

But campaigners branded the study’s launch ‘outrageous’, saying it should be halted.

The primary trial, led by King’s College London and the South London and Maudsley NHS Foundation Trust, will divide participants into two groups: one receiving puberty blockers immediately for two years, and the other delayed by one year.

Children must be under 16, have a formal diagnosis of “gender incongruence,” and obtain parental consent.

“The youngest patients in the study, being led by researchers at King’s College London, will typically be ten to 11 years old for girls and 11 to 12 years old for boys. The maximum age will be 15 years and eleven months,” the Daily Mail reports.

The drugs, such as Triptorelin, administered via injection every six months, will be monitored for side effects.

A second, smaller trial with about 100 participants will focus on potential brain development effects by comparing blocked and unblocked groups.

These studies follow the 2024 Cass Review, an independent report commissioned by NHS England that criticized the lack of high-quality evidence supporting the use of puberty blockers and led to their prohibition outside research settings.

The review highlighted risks to bone density, fertility, and mental health from prior use at the Tavistock clinic’s Gender Identity Development Service (GIDS).

The trials are part of a £10.7 million NHS-funded research program. Results are expected in about four years.

Keep reading

CDC, NIAID, DARPA Infect 36 People with Lab-Made Epidemic Influenza Virus: Journal ‘Influenza and Other Respiratory Viruses’

The U.S. military and Health and Human Services (HHS) have funded an experiment that infected 36 individuals with an epidemic influenza A/Wisconsin/67/2005 (H3N2) virus that was manufactured in a laboratory, according to a June study published in the peer-reviewed journal Influenza and Other Respiratory Viruses.

Congress, the White House, the Department of Energy, the FBI, and the CIA have confirmed that the COVID-19 pandemic was likely the result of lab-engineered pathogen manipulation.

But the government is not only engineering outbreak pathogens in the lab—they’re intentionally infecting people with them.

The influenza strain A/Wisconsin/67/2005 (H3N2) used in the new study is associated with several influenza epidemics, notably during the 2005-2006 and 2006-2007 seasons, reportedly causing widespread outbreaks.

The DARPA-funded experiment’s implications reach far beyond academic inquiry, raising grave national security concerns because lab-engineered viruses have the potential to ignite epidemics and pandemics if accidentally or deliberately released.

It also raises serious informed-consent questions, since participants who became contagious could have exposed others outside the study to a laboratory-created pathogen without their knowledge.

Keep reading

Democrats Once Again Show Veterans Come Last

The way a nation treats its veterans speaks louder than any patriotic slogan. Today, in the middle of a government shutdown, Democrats in Washington are once again showing that veterans are not their priority. 

Instead of ensuring our troops get paid on time, they are holding up a clean Republican funding bill in pursuit of subsidies and benefits for illegal immigrants. 

This indifference is not new—it reflects a pattern in American history where veterans, even those who sacrificed the most, have too often been forgotten.

That reality was made chillingly clear when Sapphire Dingler, a graduate student in public history, unearthed disturbing testimony in recently digitized U.S. archives. 

The records detailed atrocities committed by Japanese doctors during World War II against Allied prisoners of war—including Americans. 

One doctor, Hisakichi Tokuda, inspired by the infamous Unit 731, conducted gruesome experiments such as injecting soy milk intravenously into captives. 

Men suffered seizures, collapsed, and died. Their fates were recorded in dusty files that had gone largely unread for decades.

These stories were not isolated. In 1945, Italian officer Ernesto Saxida was subjected to repeated injections before dying in agony. 

American prisoners were experimented on at Kyushu Imperial University, their deaths later disguised in official records as casualties of the atomic bomb. 

Testimony at the Yokohama War Crimes Trials confirmed what many never knew: Western POWs were not spared from the horrors of Japanese medical experimentation. 

Some were literally cut open alive. And yet, for decades, these truths were obscured or buried, their memory erased twice—once by their deaths, and again by history’s silence.

Groups like Pacific Atrocities Education are now trying to correct that silence by bringing attention to the Pacific front’s forgotten brutality. 

But their work underscores a shameful fact: America has not always stood up for its veterans or even preserved their stories. At times, our government actively covered them up. 

Keep reading

National Guard “Accidentally” Gives Service Members COVID-19 Vaccine Instead of Influenza Shot

This week it was revealed that the US National Guard wrongly administered the Covid vaccine to a group of service members who were expecting to receive an influenza vaccine, according to The Epoch Times. The incident occurred during a mobile vaccination clinic for the Maine National Guard and at least one member who refused the mRNA vaccine on religious grounds received the experimental injection without his knowledge.

That service member, Mathew Bouchard, is no longer a member of the National Guard. After the incident, he felt that the trust was completely broken. He was ordered to take a flu shot and feels like he was duped. Because the incident happened close to the end of his service contract, he chose not to renew.

Bouchard explained his decision to The Epoch Times:

“Bouchard said he was ordered to receive an annual flu vaccine and went to the clinic to get that vaccine. He verified his name, date of birth, and part of his social security number, and told officials at the clinic he was there for the flu vaccine. But he was injected with a dose of a messenger RNA COVID-19 vaccine, officials told him.

‘You know how you went in for the flu shot? Well, that wasn’t a flu shot. That was a COVID-19 vaccine,’” Bouchard told The Epoch Times, recounting the meeting with superiors.

“I think, in my mind, at that point, it was like, I completely didn’t know if I trusted any people in the military,” he added.”

In addition to Bouchard, two other service members “were accidentally given a Covid vaccine” instead of a flu injection that day, Maine National Guard spokesperson Maj. Carl Lamb explained in an email to The Epoch Times. The clinic was administering both types of vaccine, which likely led to the egregious error.

“Accident” or not, the incident is inexcusable. Especially considering the recent data that has been revealed about the dangerous and deadly adverse reactions caused by the experimental mRNA vaccines – particularly among otherwise healthy young adults. Just this week, the surgeon general of Florida announced new guidelines about the vaccine that show the jab causes a stunning 84% increase in cardiac-related death among 18-39-year-old men. The state of Florida now officially recommends that young males refrain from receiving the mRNA vaccine completely.

Keep reading

Covid mRNA Vaccines Are Unregulated Military Countermeasures

mRNA Vaccines DID NOT UNDERGO a legally regulated drug approval or manufacturing process

It is important to recognize that an EUA is not part of the development pathway; it is an entirely separate entity that is used only during emergency situations and is not part of the drug approval process. (2009 Institute of Medicine of the National Academies publication, p. 28)

All mRNA products on the market and in development today became available as a result of the declared Covid pandemic, through legal pathways intended for CBRN (chemical, biological, radiological, nuclear) emergencies – in other words, war or terror incidents involving weapons of mass destruction (WMD).

These WMD-related laws include Emergency Use Authorization (EUA) and blanket legal indemnity granted through the PREP Act.

The manufacturing agreements for the Covid mRNA vaccines were military Other Transaction Agreements (OTA) signed by the Pentagon. This type of “other than contract” agreement is intended to supply the military with cutting-edge technology while bypassing pesky regulations and red tape. It is not intended for civilian use.

Keep reading

The Case of the Damning FDA Memos

On July 21, 2025, the Informed Consent Action Network (ICAN) announced that it had secured the release of over 600,000 pages of Emergency Use Authorization (EUA) data used by the US Food and Drug Administration (FDA) to authorize and approve Pfizer-BioNTech’s COVID-19 vaccine (BNT162b2), following a successful lawsuit, culminating in a late 2024 court ruling.

These documents, now publicly available on ICAN’s website, are part of a broader release of over 1.6 million pages, including data from the vaccine’s licensure in August 2021 and the earlier EUA in December 2020.

This report builds on my prior investigative work analyzing thousands of FDA documents released following the Public Health and Medical Professionals for Transparency (PHMPT) lawsuit, which focused on the biological product file submitted by Pfizer for the full approval of its COVID-19 vaccine in August 2021.

I was one of the initial researchers to uncover and analyse the damning data hidden within Pfizer’s Pregnancy & Lactation Cumulative Review, Interim-Narrative-Sensitive document (3000+ pages), and Cumulative Analysis of Post-Authorization Adverse Event Reports document, among others.

Both ICAN and PHMPT’s lawsuits sought to make public the FDA’s data on the Pfizer-BioNTech’s COVID-19 shot, asserting that transparency is critical for public trust and independent analysis, given the global administration of billions of doses of this experimental gene-based product that was mandated in several countries.

My preliminary review of ICAN’s EUA data reveals several irregularities, outlined below with references to key documents and downloadable sources. This report focuses on four critical issues: manufacturing oversight gaps, missing Bell’s palsy data, clinical trial site deficiencies, and the exclusion of unconfirmed COVID-19 cases.

Keep reading

FDA Approves Therapy For Rare Disease Without Randomized Trial Data

The Food and Drug Administration on Aug. 14 approved a therapy for a rare disease called recurrent respiratory papillomatosis (RRP).

Regulators cleared Papzimeos, an immunotherapy made by Precigen, citing data from a single-arm, open-label trial that looked at how it performed in adults with RRP and who needed at least three surgeries a year.

Patients received four injections of the therapy over 12 weeks following surgical procedures.

About half of the participants needed no surgery in the year following treatment. The safety profile was also deemed favorable.

“Randomized trials are not always needed to approve medical products and this approval is proof of that philosophy,” Dr. Vinay Prasad, director of the FDA’s Center for Biologics Evaluation and Research, said in a statement.

“The FDA will always demand the correct clinical study for the specific medical product and disease. Our requirements for products given to tens of millions of healthy people will be different than products given to at most hundreds or thousands of patients with unique diseases.”

The approval is the first announcement from Prasad after he rejoined the FDA following his July resignation.

Prasad had received criticism for not approving enough new drugs and therapies, including from the editorial board of the Wall Street Journal, which said that Prasad “has long criticized such single-arm studies that have no placebo groups.”

Replimune’s treatment for advanced melanoma is among the drugs the FDA has rejected since Prasad became its top vaccine and biologics official.

Prasad said in May that he favors randomized clinical trials but that for some rare diseases, it would be difficult or even impossible to complete such trials. He said that the FDA would have a “flexible regulatory standard” that takes into account “the context of a disease.”

In June, in an article co-authored by FDA Commissioner Dr. Marty Makary, he said that for some products targeting rare diseases, “premarket randomized trials may not be feasible.”

Keep reading

Eight Healthy Babies Born via IVF using DNA from Three People

In the United Kingdom, medical professionals have successfully delivered eight babies using a pioneering fertility procedure that incorporates DNA from three individuals.

This method aims to safeguard children from inheriting severe mitochondrial disorders. The births represent a cautious advancement in assisted reproduction, prioritizing family health and stability.

The mothers involved carried mutations in their mitochondria, risking life-threatening conditions for their offspring. Mitochondria serve as cellular energy sources, essential for bodily functions. Without intervention, these defects could devastate future generations.

The United Kingdom amended its laws in 2015 to permit this technique, reflecting deliberate ethical review. In 2017, regulators issued the initial license to Newcastle University’s fertility clinic. This institution led the development over two decades.

Among the newborns are four boys and four boys, including identical twins, from seven women. All show no evidence of the anticipated mitochondrial ailments. One additional pregnancy continues under medical care.

Professor Doug Turnbull, a key researcher, described the results as reassuring for families and scientists alike. He highlighted the relief in achieving positive outcomes for patients.

Professor Mary Herbert, a senior team member, expressed fulfillment in seeing eight healthy infants. She noted the achievement rewards the extensive collaborative work.

Human genes primarily reside in the cell’s nucleus, totaling around 20,000. However, mitochondria add 37 genes of their own. Faulty mutations here can lead to profound cellular energy deficits.

Keep reading

Meet The Dystopian Startups Making ‘Biological Computers’ From Human Cells

Picture a dystopian future where computers don’t just mimic human thinking – they’re powered by actual human brain cells. That future is taking shape in a Cambridge, England, lab, where a groundbreaking device called CL1 is blending biology and technology in ways that could transform how we compute. Developed by Australian startup Cortical Labs and U.K.-based bit.bio, this shoebox-sized machine houses 200,000 lab-grown brain cells wired to silicon circuits, creating a “biological computer” that’s already turning heads.

Unlike traditional computers, which guzzle energy, CL1 operates with the efficiency of a human brain. “Our brains process information using a fraction of the power that modern electronics need,” Hon Weng Chong, CEO of Cortical Labs, told FT. “This could open doors to smarter robots, stronger cybersecurity, and immersive virtual worlds.”

Oh, joy.

Low-energy computing has fueled a race to develop biological systems, with Cortical Labs leading alongside competitors like FinalSpark in Switzerland and Biological Black Box in the U.S.CL1’s brain cells, grown from human skin-derived stem cells, are carefully arranged in layers: one type sparks electrical activity, while another keeps it in check. “It’s like balancing a gas pedal and brakes,” Chong explains. This precision, says bit.bio’s Tony Oosterveen, gives CL1 an edge over rival approaches using less uniform “mini-brains.” The result is a platform for testing how brain cells handle information, with early experiments already yielding insights for neuroscience and drug development.

Keep reading